These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 25819867)

  • 1. Metabolic and cardiac phenotype characterization in 37 atypical Dunnigan patients with nonfarnesylated mutated prelamin A.
    Andre P; Schneebeli S; Vigouroux C; Lascols O; Schaaf M; Chevalier P
    Am Heart J; 2015 Apr; 169(4):587-93. PubMed ID: 25819867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A homozygous mutation of prelamin-A preventing its farnesylation and maturation leads to a severe lipodystrophic phenotype: new insights into the pathogenicity of nonfarnesylated prelamin-A.
    Le Dour C; Schneebeli S; Bakiri F; Darcel F; Jacquemont ML; Maubert MA; Auclair M; Jeziorowska D; Reznik Y; Béréziat V; Capeau J; Lascols O; Vigouroux C
    J Clin Endocrinol Metab; 2011 May; 96(5):E856-62. PubMed ID: 21346069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipodystrophy-linked LMNA p.R482W mutation induces clinical early atherosclerosis and in vitro endothelial dysfunction.
    Bidault G; Garcia M; Vantyghem MC; Ducluzeau PH; Morichon R; Thiyagarajah K; Moritz S; Capeau J; Vigouroux C; Béréziat V
    Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2162-71. PubMed ID: 23846499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A recurrent familial partial lipodystrophy due to a monoallelic or biallelic LMNA founder variant highlights the multifaceted cardiac manifestations of metabolic laminopathies.
    Treiber G; Flaus Furmaniuk A; Guilleux A; Medjane S; Bonfanti O; Schneebeli S; Bernard C; Le-Moullec N; Bakiri F; Pholsena M; Rollot O; Vatier C; Jarlet E; Jéru I; Lascols O; Darcel F; Domun B; Venault A; Venault S; Jacquemont ML; Doray B; Maiza JC; Cogne M; Vigouroux C; Nobécourt E
    Eur J Endocrinol; 2021 Aug; 185(4):453-462. PubMed ID: 34292171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel phenotypic expression associated with a new mutation in LMNA gene, characterized by partial lipodystrophy, insulin resistance, aortic stenosis and hypertrophic cardiomyopathy.
    Araújo-Vilar D; Lado-Abeal J; Palos-Paz F; Lattanzi G; Bandín MA; Bellido D; Domínguez-Gerpe L; Calvo C; Pérez O; Ramazanova A; Martínez-Sánchez N; Victoria B; Costa-Freitas AT
    Clin Endocrinol (Oxf); 2008 Jul; 69(1):61-8. PubMed ID: 18031308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence.
    Caron M; Auclair M; Donadille B; Béréziat V; Guerci B; Laville M; Narbonne H; Bodemer C; Lascols O; Capeau J; Vigouroux C
    Cell Death Differ; 2007 Oct; 14(10):1759-67. PubMed ID: 17612587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Familial partial lipodystrophy due to the LMNA R482W mutation with multinodular goitre, extrapyramidal syndrome and primary hyperaldosteronism.
    Vantyghem MC; Faivre-Defrance F; Marcelli-Tourvieille S; Fermon C; Evrard A; Bourdelle-Hego MF; Vigouroux C; Defebvre L; Delemer B; Wemeau JL
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):247-9. PubMed ID: 17524034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiometabolic assessment of lamin A/C gene mutation carriers: a phenotype-genotype correlation.
    Kwapich M; Lacroix D; Espiard S; Ninni S; Brigadeau F; Kouakam C; Degroote P; Laurent JM; Tiffreau V; Jannin A; Humbert L; Ben Hamou A; Tard C; Ben Yaou R; Lamblin N; Klug D; Richard P; Vigouroux C; Bonne G; Vantyghem MC;
    Diabetes Metab; 2019 Sep; 45(4):382-389. PubMed ID: 30287275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with familial partial lipodystrophy of the Dunnigan type due to a LMNA R482W mutation show muscular and cardiac abnormalities.
    Vantyghem MC; Pigny P; Maurage CA; Rouaix-Emery N; Stojkovic T; Cuisset JM; Millaire A; Lascols O; Vermersch P; Wemeau JL; Capeau J; Vigouroux C
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5337-46. PubMed ID: 15531479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Site-dependent differences in both prelamin A and adipogenic genes in subcutaneous adipose tissue of patients with type 2 familial partial lipodystrophy.
    Araújo-Vilar D; Lattanzi G; González-Méndez B; Costa-Freitas AT; Prieto D; Columbaro M; Mattioli E; Victoria B; Martínez-Sánchez N; Ramazanova A; Fraga M; Beiras A; Forteza J; Domínguez-Gerpe L; Calvo C; Lado-Abeal J
    J Med Genet; 2009 Jan; 46(1):40-8. PubMed ID: 18805829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fertility and obstetrical complications in women with LMNA-related familial partial lipodystrophy.
    Vantyghem MC; Vincent-Desplanques D; Defrance-Faivre F; Capeau J; Fermon C; Valat AS; Lascols O; Hecart AC; Pigny P; Delemer B; Vigouroux C; Wemeau JL
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2223-9. PubMed ID: 18364375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overlapping syndrome with familial partial lipodystrophy, Dunnigan variety and cardiomyopathy due to amino-terminal heterozygous missense lamin A/C mutations.
    Subramanyam L; Simha V; Garg A
    Clin Genet; 2010 Jul; 78(1):66-73. PubMed ID: 20041886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A complex case of diabetes due to LMNA mutation].
    Ambonville C; Bouldouyre MA; Laforêt P; Richard P; Benveniste O; Vigouroux C
    Rev Med Interne; 2017 Oct; 38(10):695-699. PubMed ID: 28545855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The R439C mutation in LMNA causes lamin oligomerization and susceptibility to oxidative stress.
    Verstraeten VL; Caputo S; van Steensel MA; Duband-Goulet I; Zinn-Justin S; Kamps M; Kuijpers HJ; Ostlund C; Worman HJ; Briedé JJ; Le Dour C; Marcelis CL; van Geel M; Steijlen PM; van den Wijngaard A; Ramaekers FC; Broers JL
    J Cell Mol Med; 2009 May; 13(5):959-71. PubMed ID: 19220582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LMNA-linked lipodystrophies: from altered fat distribution to cellular alterations.
    Bidault G; Vatier C; Capeau J; Vigouroux C; Béréziat V
    Biochem Soc Trans; 2011 Dec; 39(6):1752-7. PubMed ID: 22103520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homozygous and Heterozygous Nuclear Lamin A p.R582C Mutation: Different Lipodystrophic Phenotypes in the Same Kindred.
    Montenegro RM; Costa-Riquetto AD; Fernandes VO; Montenegro APDR; de Santana LS; Jorge AAL; Karbage LBAS; Aguiar LB; Carvalho FHC; Teles MG; d'Alva CB
    Front Endocrinol (Lausanne); 2018; 9():458. PubMed ID: 30177912
    [No Abstract]   [Full Text] [Related]  

  • 17. Nuclear envelope-related lipodystrophies.
    Guénantin AC; Briand N; Bidault G; Afonso P; Béréziat V; Vatier C; Lascols O; Caron-Debarle M; Capeau J; Vigouroux C
    Semin Cell Dev Biol; 2014 May; 29():148-57. PubMed ID: 24384368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Familial partial lipodystrophy (Dunnigan syndrome) due to LMNA gene mutation: The first description of its clinical case in Russia].
    Sorkina EL; Kalashnikova MF; Melnichenko GA; Tyulpakov AN
    Ter Arkh; 2015; 87(3):83-87. PubMed ID: 26027246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LMNA gene mutation search in Polish patients: new features of the heterozygous Arg482Gln mutation phenotype.
    Klupa T; Szopa M; Skupien J; Wojtyczek K; Cyganek K; Kowalska I; Malecki MT
    Endocrine; 2009 Dec; 36(3):518-23. PubMed ID: 19859838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LMNA gene mutation as a model of cardiometabolic dysfunction: from genetic analysis to treatment response.
    Chirico V; Ferraù V; Loddo I; Briuglia S; Amorini M; Salpietro V; Lacquaniti A; Salpietro C; Arrigo T
    Diabetes Metab; 2014 Jun; 40(3):224-8. PubMed ID: 24485160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.